Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Cardiotrophin 1 shows promising results for treatment of obesity and metabolic syndrome

13.09.2011
Scientists from the Center for Applied Medical Research (CIMA) of the University of Navarra (Spain) have discovered that cardiotrophin 1, a protein synthesized by muscle cells and adipose tissue, has a marked effect on fat and glucose metabolism.

"These new findings add to those we already know on this compound such the anti-ischemic and cytoprotective effects showed in acute liver damage and solid organ transplants gives CT-1 great possibilities to be developed in various serious conditions", commented Pablo Ortiz, CEO of Digna Biotech.

The study was published in the August issue of Cell Metabolism, most prestigious journal in Metabolism and further details were described in the 25th August of SciBX, the Biocentury/Nature publication. The researchers found that the administration of cardiotrophin 1 accelerates the elimination of fat from the adipose tissue and increases the rate at which fat is burnt in muscles. Treatment of obese and diabetic mice with cardiotrophin 1 increases energy expenditure, reduces food intake and corrects obesity and diabetes. Investigators noticed that, in addition to its effects on fat metabolism, cardiotrophin 1 promotes the entrance of glucose into the cells and increases the sensitivity to insulin. The investigation has been led by M. Bustos, J. Prieto and MJ Moreno-Aliaga at CIMA.

Cardiotrophin 1 is co-developed for its use in organ transplantation and tissue regeneration by Digna Biotech and Biotecnol (The Consortium). Both of the companies signed an Exclusive License and Option Agreement with Genentech, Inc (a fully owned subsidiary of the Roche group) on September 2009. Pablo Ortiz remarked: "Cardiotrophin 1 showed a very interesting effect on fat metabolism which deserves to be explored in a clinical setting. We are ready to recruit healthy volunteers in the Phase I trial before the end of the year. Phase II in liver resection is scheduled for the second quarter of 2012. We are also confident that these new applications and the progress on the clinical development will allow us to forge partnerships with other biopharmaceutical companies to reach the patients as soon as possible". According to Pedro de Noronha Pissarra, CEO of Biotecnol: "expanding the use of such a promising molecule to other fields of use, where unmet needs exist, will build additional value to the current work. Its clear from the current findings on the mechanism of action of Cardiotrophin 1 in fat metabolism, that clinical work should be pursued and potentially new partnerships in order to expand such work can now be equated".

Pre-clinicial and clinical development of cardiotrophin 1 was funded by private and public Spanish entities: ClaveSuan, the Center for Industrial and Technological Development (CDTI), and the Government of Navarra. Only in liver resection and transplantation, cardiotrophin 1 may generate revenues of 350 millions of euros per year.

About Cardiotrophin 1 (CT-1)

Cardiotrophin 1 is a member of the interleukin-6 cytokine family. Recently, investigators from the Centre for Applied Medical Research (CIMA) have discovered that this protein is able to stimulate hepatic regeneration as well as to protect hepatocytes during clinical situations of acute hepatic damage. This means that CT-1 may be beneficial for those patients who undergo liver transplantation or extensive hepatic resection. The use of CT-1 in liver transplantation has already been granted Orphan Drug Status by both the FDA and the EMEA. In addition, cardiotrophin 1 has recently been shown to prevent graft injury and inflammatory response and prolong survival in animal kidney transplant model, and acute liver failure.

About Digna Biotech

Digna Biotech, a biotechnological company, is a spin-off of the University of Navarra (Pamplona, Spain) and is funded by a group of investors representing some of Spain's major corporations and financial institutions. It is committed to develop new drugs based on the IP generated by the Center for Applied Medical Research (CIMA) and to forge partnerships with pharmaceutical industry to ensure complete clinical development and commercial launch. Its extensive pipeline reflects the four major avenues of research pursued by CIMA: Cardiovascular, Gene Therapy, Hepatology and Oncology. Inspired by similar university-industry collaboration projects in USA, Digna Biotech presents a pioneering business model in Spain.. In cooperation with CIMA, CIFA (Center For Applied Pharmacobiology Research), a number of Schools of the University of Navarra (especially the School of Pharmacy and its Galenic Department), and the Clínica Universidad de Navarra, Digna Biotech is carrying out a range of activities to ensure the clinical trial development of the products. As a direct result of the company's commitment to translational research and focus on delivering meaningful health outcomes, and thanks to the effort made by the staff of Digna Biotech and CIMA, three products are now in the clinical phase. The company plans to enter a new product every year in clinical trials to reach the patient with innovative products for unmet medical needs. More information. www.dignabiotech.com and www.cima.es

About Biotecnol

Biotecnol is a biotechnology company developing biopharmaceutical products, and has a special focus on the development of novel antibody-based therapeutics to treat life-threatening diseases such as cancer. Biotecnol has a proprietary antibody format, which allows to develop multi-specific antibodies against various cancer targets. These formats are called Tribodies™. Biotecnol is committed in building value by developing a diverse pipeline of antibody products to address unmet healthcare needs. Through its facilities in Portugal, Biotecnol leverages its business income by establishing in-house partner-led or collaborative programmes, which provide Biotecnol a strong client-based activity and an established track record. Biotecnol uses its proprietary expression technology, cell line development capabilities, upstream and downstream processing, analytics and QC experience for delivering therapeutic recombinant protein product and processes to support all stages of product development through early research and preclinical activities to GMP/GLP compliant processes for biomanufacturing of clinical and ultimately commercial products. More Information: www.biotecnol.com

Nuria Safont | EurekAlert!
Further information:
http://www.dignabiotech.com
http://www.biotecnol.com

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>